Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
2007-06-05
2007-06-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S250000, C540S494000, C540S556000, C544S343000
Reissue Patent
active
11356421
ABSTRACT:
The present invention is directed to certain novel compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
REFERENCES:
patent: 3299078 (1967-01-01), Pachter
patent: 3813392 (1974-05-01), Sellstedt et al.
patent: 3891643 (1975-06-01), Sellstedt et al.
patent: 3892746 (1975-07-01), Sellstedt et al.
patent: 3914421 (1975-10-01), Rajogopalan
patent: 4013652 (1977-03-01), Rajagopalan
patent: 4088647 (1978-05-01), Glushkov et al.
patent: 4115577 (1978-09-01), Rajagopalan
patent: 4183936 (1980-01-01), Rajagopalan
patent: 4219550 (1980-08-01), Rajagopalan
patent: 4238607 (1980-12-01), Rajagopalan
patent: 4997831 (1991-03-01), Bays et al.
patent: 5100884 (1992-03-01), Hamminga et al.
patent: 5223625 (1993-06-01), Van Wijngaarden et al.
patent: 5328905 (1994-07-01), Hamminga et al.
patent: 5512575 (1996-04-01), Jacobs et al.
patent: 5654139 (1997-08-01), Lappalainen et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 5908830 (1999-06-01), Smith et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6407092 (2002-06-01), Hester et al.
patent: 200043637 (2000-11-01), None
patent: 2011107 (1991-08-01), None
patent: 0725068 (1996-08-01), None
patent: 2213283 (1974-02-01), None
patent: WO 0064899 (2000-11-01), None
Bickerdike MJ, Vickers, SP, Dourish CT. (1999) 5-HT2C receptor modulation and the treatment of obesity. Diabetes, Obesity and Metabolism 1:207-214.
Tecott LH, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature (London) 374:542-546.
Cryan JF, Lucki I, (2000) antidepressant-like behavioral effects mediated by 5-hydroxtryptamine2C receptors. J. Pharmacol. Exper. Ther. 295:1120-1126.
Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S, (1997) 5-HT2C receptors mediate penile erection in rats: actions of novel and selective agonists and antagonists. Eur. J. Pharmacol. 325:9-12.
Martin JR, et al. (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exper. Ther. 286:913-924.
Meltzer HY. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (2) :1065-1155.
Curzon et al, Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability, TiPS, vol. 18, 1997; 21-25.
Mora et al, Role of 5-HT2A and 5-HT2C Receptor subtypes in the Two Types of Fear Generated by the Elevated T-Maze, Pharma. Biolchem. & Behavior, vol. 58, No. 4, 1997; 1051-1057.
Jenck et al, Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats, European Neuropsychopharmacology, 8, 1998; 161-168.
Leysen, Selective 5-HT2c agonists as potential antidepressants, Drugs, 1999, 2 (2); 109-120.
Jenck et al, The role of 5-HT2c receptors in affective disorders, Exp. Opin. Invest. Drugs, 1998, 7(10): 1587-1599.
Kennett, 5-HT drugs and eating disorders, I Drugs, 1998, vol. 1, No. 4; 456-470.
Brewerton, Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine, Clin. Pharmacol. Ther., 1988, 605-609.
Kahn et al, m-Chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 1991; 30: 1139-1166.
Gibson et al, Evidence that mCPP-induced Anxiety in the Plus-maze is mediated by Postsynaptic 5-HT2c receptors but not by sympathomimetic effects, Neuropharmacology, vol. 33, No. 3, 4, 1994; 457-465.
Calvello Emile J. B.
Chen Wenting
Deng Wei
Haydar Simon
Lee Taekyu
Bristol-Myers Squibb Pharma Company
Duncan, Jr. Sammy G.
Kifle Bruck
LandOfFree
Substituted heterocycle fused gamma-carbolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocycle fused gamma-carbolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocycle fused gamma-carbolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861855